This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor:—
Johansen and Erickson, in their article entitled "Current Status of Therapy in Leprosy" in The Journal (144:985 [Nov. 18] 1950), give adequate information by reference or otherwise as to the origin and source of the compounds they used, except 4-amino,4′-beta-hydroxy-ethylaminodiphenylsulfone (HES). This compound was synthesized, studied and tested for activity in experimental tuberculosis for the first time in the laboratories of the National Institutes of Health by my associates and me (Smith, M. I.; Jackson, E. L.; Junge, J. M., and Bhattacharya, B. K.: Am. Rev. Tuberc.60:62 [July] 1949; Smith, M. I.; Jackson, E. L., and Bauer, H.: Ann. New York Acad. Sc.52:704 [Dec.] 1949). The compound was generously supplied by Merck & Company, Inc., through Dr. Augustus Gibson, who offered to make it in sufficient quantity to be available for clinical tests in tuberculosis and leprosy. The work on tuberculosis has
Smith MI. SULFONES IN THE CHEMOTHERAPY OF LEPROSY. JAMA. 1951;145(2):106. doi:10.1001/jama.1951.02920200046021